| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 102 | 2024 | 257 | 22.950 |
Why?
|
| Solitary Pulmonary Nodule | 31 | 2022 | 32 | 7.610 |
Why?
|
| Tomography, X-Ray Computed | 46 | 2022 | 205 | 6.990 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 24 | 2022 | 50 | 5.940 |
Why?
|
| Early Detection of Cancer | 29 | 2024 | 510 | 5.650 |
Why?
|
| Humans | 225 | 2024 | 18058 | 4.420 |
Why?
|
| Practice Guidelines as Topic | 22 | 2017 | 324 | 3.260 |
Why?
|
| Neoplasm Staging | 31 | 2022 | 330 | 3.160 |
Why?
|
| Mass Screening | 19 | 2022 | 678 | 2.910 |
Why?
|
| Positron-Emission Tomography | 18 | 2017 | 26 | 2.750 |
Why?
|
| Lung | 11 | 2023 | 46 | 2.590 |
Why?
|
| Emergency Service, Hospital | 10 | 2020 | 357 | 2.560 |
Why?
|
| Multiple Pulmonary Nodules | 9 | 2022 | 11 | 2.400 |
Why?
|
| Female | 106 | 2023 | 12838 | 2.380 |
Why?
|
| Evidence-Based Medicine | 16 | 2016 | 195 | 2.370 |
Why?
|
| Male | 101 | 2022 | 10173 | 2.370 |
Why?
|
| Smoking | 12 | 2022 | 465 | 2.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 10 | 2022 | 163 | 2.140 |
Why?
|
| Aged | 68 | 2022 | 6258 | 2.120 |
Why?
|
| Anti-Bacterial Agents | 8 | 2020 | 138 | 2.110 |
Why?
|
| Retrospective Studies | 35 | 2023 | 2498 | 2.100 |
Why?
|
| Middle Aged | 74 | 2022 | 8073 | 2.010 |
Why?
|
| Societies, Medical | 17 | 2023 | 71 | 2.000 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 1023 | 1.890 |
Why?
|
| Sinusitis | 4 | 2017 | 14 | 1.890 |
Why?
|
| Venous Thromboembolism | 10 | 2020 | 50 | 1.880 |
Why?
|
| Guideline Adherence | 11 | 2017 | 160 | 1.850 |
Why?
|
| Risk Assessment | 25 | 2020 | 1137 | 1.840 |
Why?
|
| Adenocarcinoma | 6 | 2016 | 177 | 1.760 |
Why?
|
| Pulmonary Medicine | 6 | 2019 | 15 | 1.750 |
Why?
|
| Diagnostic Imaging | 7 | 2020 | 43 | 1.680 |
Why?
|
| Critical Illness | 8 | 2022 | 53 | 1.680 |
Why?
|
| Pulmonary Embolism | 11 | 2020 | 43 | 1.650 |
Why?
|
| United States | 44 | 2023 | 4119 | 1.620 |
Why?
|
| Hospitalization | 8 | 2024 | 813 | 1.540 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2017 | 55 | 1.470 |
Why?
|
| Hospital Mortality | 6 | 2022 | 150 | 1.430 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2017 | 351 | 1.410 |
Why?
|
| Delivery of Health Care, Integrated | 7 | 2020 | 552 | 1.400 |
Why?
|
| Fibrinolytic Agents | 8 | 2017 | 44 | 1.380 |
Why?
|
| Fluorodeoxyglucose F18 | 9 | 2016 | 11 | 1.360 |
Why?
|
| Unnecessary Procedures | 6 | 2019 | 24 | 1.350 |
Why?
|
| Venous Thrombosis | 7 | 2017 | 20 | 1.320 |
Why?
|
| Aged, 80 and over | 26 | 2022 | 1956 | 1.300 |
Why?
|
| Patient Selection | 8 | 2024 | 194 | 1.250 |
Why?
|
| Pulmonary Fibrosis | 6 | 2008 | 10 | 1.240 |
Why?
|
| Outcome Assessment (Health Care) | 10 | 2018 | 248 | 1.190 |
Why?
|
| Pandemics | 6 | 2022 | 293 | 1.170 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 144 | 1.160 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2022 | 60 | 1.160 |
Why?
|
| Decision Support Techniques | 6 | 2013 | 92 | 1.160 |
Why?
|
| Critical Care | 7 | 2023 | 72 | 1.130 |
Why?
|
| Prognosis | 17 | 2020 | 619 | 1.100 |
Why?
|
| Referral and Consultation | 2 | 2022 | 178 | 1.050 |
Why?
|
| Risk Factors | 29 | 2022 | 3394 | 1.050 |
Why?
|
| Predictive Value of Tests | 14 | 2023 | 350 | 1.040 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 50 | 1.030 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 57 | 1.030 |
Why?
|
| Quality Assurance, Health Care | 5 | 2014 | 188 | 1.020 |
Why?
|
| Depression | 6 | 2023 | 512 | 1.010 |
Why?
|
| Quality of Life | 11 | 2019 | 509 | 1.000 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2022 | 11 | 0.970 |
Why?
|
| Lung Diseases | 7 | 2016 | 32 | 0.940 |
Why?
|
| Tomography, Emission-Computed | 6 | 2003 | 6 | 0.930 |
Why?
|
| Anticoagulants | 9 | 2022 | 122 | 0.920 |
Why?
|
| Pneumonia | 3 | 2019 | 54 | 0.910 |
Why?
|
| Quality of Health Care | 4 | 2018 | 346 | 0.900 |
Why?
|
| Veterans | 5 | 2022 | 135 | 0.890 |
Why?
|
| Lymph Nodes | 3 | 2017 | 17 | 0.880 |
Why?
|
| Treatment Outcome | 20 | 2020 | 1259 | 0.860 |
Why?
|
| Heparin | 7 | 2014 | 9 | 0.860 |
Why?
|
| Incidental Findings | 5 | 2022 | 30 | 0.850 |
Why?
|
| Radiography, Thoracic | 9 | 2020 | 18 | 0.850 |
Why?
|
| Patient Readmission | 2 | 2014 | 161 | 0.850 |
Why?
|
| Sensitivity and Specificity | 19 | 2016 | 318 | 0.850 |
Why?
|
| Postoperative Complications | 6 | 2017 | 101 | 0.830 |
Why?
|
| Adult | 40 | 2022 | 7696 | 0.830 |
Why?
|
| Surveys and Questionnaires | 16 | 2022 | 1346 | 0.820 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 25 | 0.820 |
Why?
|
| Betacoronavirus | 3 | 2020 | 36 | 0.810 |
Why?
|
| Radiopharmaceuticals | 9 | 2016 | 12 | 0.800 |
Why?
|
| Exercise Therapy | 4 | 2019 | 70 | 0.790 |
Why?
|
| Probability | 7 | 2022 | 86 | 0.780 |
Why?
|
| Catheterization, Central Venous | 2 | 2016 | 11 | 0.780 |
Why?
|
| Community Health Services | 1 | 2022 | 85 | 0.780 |
Why?
|
| Prospective Studies | 16 | 2017 | 1294 | 0.770 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 25 | 0.770 |
Why?
|
| Clinical Competence | 4 | 2017 | 109 | 0.770 |
Why?
|
| Mediastinal Neoplasms | 3 | 2006 | 3 | 0.770 |
Why?
|
| Medical Overuse | 2 | 2018 | 13 | 0.770 |
Why?
|
| Algorithms | 7 | 2012 | 235 | 0.750 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 454 | 0.750 |
Why?
|
| Decision Making | 6 | 2022 | 204 | 0.750 |
Why?
|
| Cytokines | 1 | 2020 | 27 | 0.740 |
Why?
|
| Watchful Waiting | 2 | 2019 | 18 | 0.740 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 1255 | 0.740 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2020 | 7 | 0.730 |
Why?
|
| Intensive Care Units | 8 | 2022 | 103 | 0.720 |
Why?
|
| Thrombolytic Therapy | 3 | 2009 | 21 | 0.710 |
Why?
|
| Heparin, Low-Molecular-Weight | 6 | 2017 | 10 | 0.700 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 15 | 0.690 |
Why?
|
| California | 13 | 2017 | 2327 | 0.690 |
Why?
|
| Patient Discharge | 3 | 2016 | 150 | 0.680 |
Why?
|
| Time Factors | 11 | 2015 | 1114 | 0.680 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 29 | 0.670 |
Why?
|
| Bronchoscopy | 5 | 2017 | 8 | 0.670 |
Why?
|
| Hypertension, Pulmonary | 3 | 2009 | 8 | 0.660 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2016 | 23 | 0.650 |
Why?
|
| Survival Rate | 10 | 2016 | 266 | 0.640 |
Why?
|
| Outcome and Process Assessment (Health Care) | 4 | 2017 | 106 | 0.640 |
Why?
|
| Endosonography | 3 | 2017 | 9 | 0.630 |
Why?
|
| Cost-Benefit Analysis | 12 | 2017 | 264 | 0.620 |
Why?
|
| Education, Continuing | 1 | 2017 | 3 | 0.620 |
Why?
|
| Antimicrobial Stewardship | 1 | 2017 | 6 | 0.620 |
Why?
|
| Diagnosis, Differential | 11 | 2014 | 58 | 0.620 |
Why?
|
| Hemorrhage | 9 | 2020 | 63 | 0.610 |
Why?
|
| Mediastinum | 1 | 2017 | 1 | 0.610 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 10 | 0.610 |
Why?
|
| Population Surveillance | 2 | 2016 | 270 | 0.600 |
Why?
|
| Sleep Wake Disorders | 3 | 2016 | 40 | 0.590 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 42 | 0.590 |
Why?
|
| Pragmatic Clinical Trials as Topic | 4 | 2022 | 53 | 0.590 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 233 | 0.580 |
Why?
|
| Lung Transplantation | 4 | 2009 | 7 | 0.570 |
Why?
|
| Sepsis | 2 | 2016 | 71 | 0.570 |
Why?
|
| Registries | 6 | 2019 | 486 | 0.560 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 3 | 0.560 |
Why?
|
| Neuroimaging | 1 | 2016 | 3 | 0.550 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 24 | 0.550 |
Why?
|
| Electronic Health Records | 7 | 2017 | 734 | 0.540 |
Why?
|
| Cohort Studies | 12 | 2022 | 2631 | 0.530 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2013 | 2 | 0.530 |
Why?
|
| Logistic Models | 9 | 2017 | 953 | 0.530 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 103 | 0.510 |
Why?
|
| Biomedical Research | 4 | 2020 | 89 | 0.500 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 5 | 0.480 |
Why?
|
| Hospitals, Veterans | 4 | 2014 | 34 | 0.480 |
Why?
|
| Primary Health Care | 4 | 2017 | 843 | 0.470 |
Why?
|
| Motor Activity | 2 | 2015 | 208 | 0.450 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 2 | 0.450 |
Why?
|
| Ambulatory Care | 1 | 2015 | 274 | 0.440 |
Why?
|
| Quality Indicators, Health Care | 2 | 2014 | 197 | 0.440 |
Why?
|
| Thoracic Diseases | 1 | 2012 | 2 | 0.440 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 481 | 0.440 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 11 | 0.440 |
Why?
|
| Physicians, Primary Care | 1 | 2013 | 75 | 0.430 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 2 | 0.430 |
Why?
|
| Drug Costs | 2 | 2014 | 39 | 0.430 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 7 | 0.430 |
Why?
|
| Age Factors | 8 | 2020 | 945 | 0.430 |
Why?
|
| Comorbidity | 8 | 2022 | 618 | 0.430 |
Why?
|
| Medical Oncology | 2 | 2023 | 33 | 0.430 |
Why?
|
| Biopsy | 4 | 2016 | 73 | 0.430 |
Why?
|
| Asthma | 3 | 2007 | 302 | 0.420 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 15 | 0.410 |
Why?
|
| Cause of Death | 2 | 2015 | 181 | 0.410 |
Why?
|
| Natural Language Processing | 1 | 2012 | 53 | 0.410 |
Why?
|
| Withholding Treatment | 1 | 2011 | 26 | 0.400 |
Why?
|
| Acute Disease | 5 | 2017 | 138 | 0.400 |
Why?
|
| Respiration, Artificial | 4 | 2023 | 36 | 0.400 |
Why?
|
| Biopsy, Needle | 6 | 2013 | 13 | 0.400 |
Why?
|
| Delivery of Health Care | 6 | 2022 | 445 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2022 | 328 | 0.390 |
Why?
|
| Thromboembolism | 2 | 2014 | 33 | 0.390 |
Why?
|
| Sex Factors | 7 | 2016 | 634 | 0.390 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 81 | 0.380 |
Why?
|
| Health Status | 4 | 2016 | 331 | 0.380 |
Why?
|
| Odds Ratio | 5 | 2015 | 692 | 0.380 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 595 | 0.380 |
Why?
|
| Antiviral Agents | 2 | 2009 | 96 | 0.370 |
Why?
|
| Attitude to Health | 4 | 2012 | 179 | 0.370 |
Why?
|
| Health Priorities | 2 | 2020 | 28 | 0.370 |
Why?
|
| Chronic Disease | 5 | 2022 | 462 | 0.370 |
Why?
|
| Anxiety | 4 | 2022 | 153 | 0.370 |
Why?
|
| Models, Biological | 2 | 2007 | 32 | 0.370 |
Why?
|
| Patient Care Team | 3 | 2016 | 130 | 0.370 |
Why?
|
| Mediastinoscopy | 4 | 2017 | 5 | 0.370 |
Why?
|
| Research Design | 9 | 2020 | 393 | 0.360 |
Why?
|
| Medical Audit | 2 | 2016 | 40 | 0.360 |
Why?
|
| Incidence | 6 | 2015 | 1297 | 0.360 |
Why?
|
| National Health Programs | 1 | 2009 | 10 | 0.360 |
Why?
|
| Neuraminidase | 1 | 2009 | 1 | 0.350 |
Why?
|
| Zanamivir | 1 | 2009 | 1 | 0.350 |
Why?
|
| Oseltamivir | 1 | 2009 | 3 | 0.350 |
Why?
|
| Survival Analysis | 6 | 2017 | 225 | 0.340 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 39 | 0.340 |
Why?
|
| Disease Progression | 8 | 2019 | 255 | 0.330 |
Why?
|
| ROC Curve | 5 | 2017 | 79 | 0.330 |
Why?
|
| Mentoring | 2 | 2019 | 28 | 0.330 |
Why?
|
| Radiation Dosage | 5 | 2019 | 16 | 0.330 |
Why?
|
| Pulmonary Artery | 1 | 2008 | 3 | 0.320 |
Why?
|
| Respiration | 1 | 2008 | 6 | 0.320 |
Why?
|
| Health Care Costs | 2 | 2009 | 253 | 0.320 |
Why?
|
| Quality Improvement | 4 | 2020 | 205 | 0.320 |
Why?
|
| Survivors | 2 | 2022 | 157 | 0.320 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2007 | 1 | 0.310 |
Why?
|
| Respiratory Insufficiency | 2 | 2023 | 16 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 20 | 0.310 |
Why?
|
| Research | 3 | 2023 | 73 | 0.300 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 113 | 0.300 |
Why?
|
| Professional-Patient Relations | 2 | 2017 | 49 | 0.300 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2007 | 67 | 0.300 |
Why?
|
| Postoperative Hemorrhage | 2 | 2017 | 8 | 0.300 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 53 | 0.300 |
Why?
|
| Research Report | 2 | 2020 | 22 | 0.290 |
Why?
|
| Walking | 3 | 2019 | 87 | 0.290 |
Why?
|
| Qualitative Research | 3 | 2023 | 267 | 0.290 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 147 | 0.290 |
Why?
|
| Pneumonectomy | 2 | 2016 | 7 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 393 | 0.280 |
Why?
|
| Culture | 2 | 2016 | 29 | 0.280 |
Why?
|
| Attitude of Health Personnel | 3 | 2017 | 227 | 0.270 |
Why?
|
| Influenza, Human | 1 | 2009 | 277 | 0.270 |
Why?
|
| Oxyhemoglobins | 1 | 2005 | 1 | 0.270 |
Why?
|
| Pyridones | 1 | 2005 | 7 | 0.270 |
Why?
|
| Sickness Impact Profile | 2 | 2005 | 22 | 0.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 177 | 0.270 |
Why?
|
| Cough | 2 | 2015 | 17 | 0.260 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 68 | 0.260 |
Why?
|
| Dalteparin | 2 | 2014 | 2 | 0.260 |
Why?
|
| Epoprostenol | 1 | 2004 | 1 | 0.250 |
Why?
|
| Preventive Health Services | 2 | 2017 | 164 | 0.250 |
Why?
|
| Stroke | 3 | 2016 | 306 | 0.250 |
Why?
|
| Young Adult | 6 | 2020 | 2479 | 0.240 |
Why?
|
| Enteral Nutrition | 1 | 2004 | 6 | 0.240 |
Why?
|
| Observational Studies as Topic | 2 | 2022 | 49 | 0.240 |
Why?
|
| Judgment | 1 | 2024 | 2 | 0.240 |
Why?
|
| Veterans Health | 2 | 2014 | 21 | 0.240 |
Why?
|
| Mammography | 2 | 2015 | 173 | 0.240 |
Why?
|
| Adolescent | 9 | 2020 | 3714 | 0.230 |
Why?
|
| Noninvasive Ventilation | 1 | 2023 | 10 | 0.220 |
Why?
|
| Hospital Costs | 3 | 2014 | 40 | 0.220 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 170 | 0.220 |
Why?
|
| Cross Infection | 1 | 2003 | 27 | 0.220 |
Why?
|
| Dexamethasone | 1 | 2022 | 10 | 0.220 |
Why?
|
| Medical Records | 3 | 2015 | 108 | 0.220 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 667 | 0.220 |
Why?
|
| Spinal Cord Injuries | 1 | 2002 | 5 | 0.220 |
Why?
|
| Policy | 1 | 2022 | 19 | 0.210 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 745 | 0.210 |
Why?
|
| Patient Education as Topic | 2 | 2022 | 215 | 0.210 |
Why?
|
| Managed Care Programs | 2 | 2015 | 356 | 0.210 |
Why?
|
| Ventilators, Mechanical | 1 | 2002 | 1 | 0.210 |
Why?
|
| Pneumonia, Bacterial | 1 | 2002 | 7 | 0.210 |
Why?
|
| Radiography | 4 | 2015 | 39 | 0.210 |
Why?
|
| Needs Assessment | 1 | 2002 | 73 | 0.210 |
Why?
|
| Respiratory Function Tests | 3 | 2013 | 20 | 0.210 |
Why?
|
| Immunologic Factors | 2 | 2019 | 27 | 0.200 |
Why?
|
| Urologic Surgical Procedures | 3 | 2017 | 7 | 0.200 |
Why?
|
| Exercise Test | 2 | 2015 | 43 | 0.200 |
Why?
|
| Inpatients | 2 | 2020 | 79 | 0.200 |
Why?
|
| Cross-Sectional Studies | 5 | 2016 | 1309 | 0.200 |
Why?
|
| Health Services Research | 3 | 2022 | 271 | 0.200 |
Why?
|
| Glucose-6-Phosphate | 1 | 2001 | 1 | 0.200 |
Why?
|
| Smoking Cessation | 3 | 2017 | 198 | 0.200 |
Why?
|
| Women's Health | 1 | 2002 | 208 | 0.200 |
Why?
|
| Aging | 1 | 2002 | 159 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 123 | 0.190 |
Why?
|
| Radiologists | 1 | 2020 | 4 | 0.190 |
Why?
|
| Bacterial Infections | 1 | 2000 | 10 | 0.190 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2000 | 1 | 0.190 |
Why?
|
| Canada | 3 | 2017 | 66 | 0.190 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 16 | 0.190 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 131 | 0.190 |
Why?
|
| Confidence Intervals | 3 | 2008 | 249 | 0.190 |
Why?
|
| Urinary Tract Infections | 1 | 2000 | 20 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 205 | 0.190 |
Why?
|
| Early Medical Intervention | 1 | 2020 | 10 | 0.190 |
Why?
|
| Patient Portals | 1 | 2021 | 25 | 0.190 |
Why?
|
| Government Programs | 1 | 2020 | 11 | 0.190 |
Why?
|
| Counseling | 1 | 2022 | 199 | 0.190 |
Why?
|
| Medicare | 3 | 2022 | 206 | 0.180 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2020 | 3 | 0.180 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 705 | 0.180 |
Why?
|
| Cephalosporins | 1 | 2020 | 8 | 0.180 |
Why?
|
| Research Personnel | 1 | 2020 | 30 | 0.180 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 54 | 0.180 |
Why?
|
| Likelihood Functions | 2 | 2012 | 49 | 0.180 |
Why?
|
| Models, Statistical | 2 | 2020 | 184 | 0.180 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 42 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 94 | 0.180 |
Why?
|
| Genes, cdc | 1 | 2019 | 1 | 0.180 |
Why?
|
| Income | 2 | 2017 | 95 | 0.170 |
Why?
|
| Editorial Policies | 1 | 2019 | 5 | 0.170 |
Why?
|
| Mental Disorders | 1 | 2022 | 290 | 0.170 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 14 | 0.170 |
Why?
|
| Sex Distribution | 3 | 2015 | 192 | 0.170 |
Why?
|
| Age Distribution | 3 | 2015 | 257 | 0.170 |
Why?
|
| Bronchodilator Agents | 2 | 2015 | 14 | 0.170 |
Why?
|
| Meta-Analysis as Topic | 1 | 1998 | 35 | 0.160 |
Why?
|
| Thrombosis | 2 | 2012 | 11 | 0.160 |
Why?
|
| Patient Transfer | 1 | 2018 | 24 | 0.160 |
Why?
|
| Health Care Surveys | 2 | 2016 | 252 | 0.160 |
Why?
|
| Disease Management | 2 | 2016 | 143 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2014 | 42 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 397 | 0.150 |
Why?
|
| Simulation Training | 1 | 2017 | 4 | 0.150 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1997 | 1 | 0.150 |
Why?
|
| Multilevel Analysis | 1 | 2017 | 13 | 0.150 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 14 | 0.150 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 15 | 0.150 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2017 | 22 | 0.150 |
Why?
|
| Efficiency, Organizational | 1 | 2017 | 37 | 0.150 |
Why?
|
| Students, Medical | 1 | 2017 | 17 | 0.150 |
Why?
|
| Tobacco Use Disorder | 1 | 2017 | 50 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 7 | 0.150 |
Why?
|
| Patient Care | 1 | 2017 | 37 | 0.150 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 17 | 0.150 |
Why?
|
| Urologic Diseases | 1 | 2017 | 8 | 0.150 |
Why?
|
| Pulmonologists | 1 | 2017 | 1 | 0.150 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 1997 | 1 | 0.150 |
Why?
|
| Communication | 2 | 2023 | 205 | 0.150 |
Why?
|
| Hypoxia | 1 | 1997 | 7 | 0.150 |
Why?
|
| Respiratory Distress Syndrome, Adult | 1 | 1997 | 9 | 0.150 |
Why?
|
| Data Collection | 5 | 2013 | 276 | 0.150 |
Why?
|
| Oncologists | 1 | 2016 | 7 | 0.150 |
Why?
|
| Sleep Medicine Specialty | 1 | 2016 | 5 | 0.140 |
Why?
|
| Asia | 1 | 2016 | 15 | 0.140 |
Why?
|
| Aspirin | 1 | 2017 | 67 | 0.140 |
Why?
|
| Length of Stay | 2 | 2010 | 182 | 0.140 |
Why?
|
| Palliative Care | 1 | 2017 | 57 | 0.140 |
Why?
|
| False Positive Reactions | 1 | 2016 | 26 | 0.140 |
Why?
|
| Learning | 1 | 2016 | 10 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2016 | 18 | 0.140 |
Why?
|
| Hospitals, Community | 1 | 2016 | 23 | 0.140 |
Why?
|
| Translational Medical Research | 1 | 2016 | 38 | 0.140 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 31 | 0.140 |
Why?
|
| Advisory Committees | 1 | 2017 | 111 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2016 | 29 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 236 | 0.140 |
Why?
|
| Health Resources | 1 | 2016 | 36 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2016 | 20 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 8 | 0.140 |
Why?
|
| Mid-Atlantic Region | 1 | 2015 | 8 | 0.140 |
Why?
|
| Hypertension | 1 | 2020 | 489 | 0.140 |
Why?
|
| Sampling Studies | 1 | 2015 | 51 | 0.140 |
Why?
|
| Northwestern United States | 1 | 2015 | 47 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 48 | 0.130 |
Why?
|
| Pediatrics | 1 | 2017 | 164 | 0.130 |
Why?
|
| Habits | 1 | 2015 | 7 | 0.130 |
Why?
|
| Somatoform Disorders | 1 | 2015 | 6 | 0.130 |
Why?
|
| Tics | 1 | 2015 | 3 | 0.130 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 643 | 0.130 |
Why?
|
| Focus Groups | 4 | 2016 | 152 | 0.130 |
Why?
|
| Recurrence | 3 | 2000 | 186 | 0.130 |
Why?
|
| Health Status Indicators | 2 | 2005 | 66 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 118 | 0.130 |
Why?
|
| Ethnic Groups | 2 | 2016 | 504 | 0.130 |
Why?
|
| Consensus | 3 | 2020 | 40 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2016 | 145 | 0.120 |
Why?
|
| Infant | 2 | 2016 | 1212 | 0.120 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 123 | 0.120 |
Why?
|
| Health Facilities | 1 | 2014 | 18 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 97 | 0.120 |
Why?
|
| Reproducibility of Results | 5 | 2008 | 394 | 0.120 |
Why?
|
| Internet | 1 | 2016 | 247 | 0.120 |
Why?
|
| Insurance Coverage | 2 | 2016 | 136 | 0.120 |
Why?
|
| Health Expenditures | 1 | 2014 | 81 | 0.120 |
Why?
|
| Health Services Accessibility | 2 | 2014 | 316 | 0.120 |
Why?
|
| Biomarkers | 3 | 2012 | 306 | 0.120 |
Why?
|
| Exercise | 1 | 2018 | 478 | 0.120 |
Why?
|
| National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division | 1 | 2013 | 5 | 0.110 |
Why?
|
| Physical Examination | 1 | 2013 | 21 | 0.110 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 13 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2014 | 126 | 0.110 |
Why?
|
| Medical History Taking | 1 | 2013 | 35 | 0.110 |
Why?
|
| Anti-Infective Agents | 2 | 2003 | 14 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 21 | 0.110 |
Why?
|
| Patient Preference | 1 | 2013 | 49 | 0.110 |
Why?
|
| Policy Making | 1 | 2012 | 18 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 228 | 0.110 |
Why?
|
| APACHE | 1 | 2012 | 11 | 0.110 |
Why?
|
| Telemedicine | 1 | 2016 | 187 | 0.110 |
Why?
|
| Insurance, Health | 2 | 2014 | 221 | 0.110 |
Why?
|
| Information Dissemination | 1 | 2012 | 55 | 0.110 |
Why?
|
| Stockings, Compression | 1 | 2012 | 1 | 0.100 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2012 | 2 | 0.100 |
Why?
|
| Aminoglycosides | 2 | 2003 | 3 | 0.100 |
Why?
|
| Fluoroquinolones | 2 | 2003 | 7 | 0.100 |
Why?
|
| Health Services Misuse | 1 | 2011 | 14 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 28 | 0.100 |
Why?
|
| Censuses | 1 | 2012 | 32 | 0.100 |
Why?
|
| Prevalence | 4 | 2015 | 892 | 0.100 |
Why?
|
| Hispanic Americans | 2 | 2012 | 431 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 202 | 0.100 |
Why?
|
| Confounding Factors (Epidemiology) | 2 | 2010 | 97 | 0.100 |
Why?
|
| Personality Tests | 1 | 1990 | 1 | 0.090 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2010 | 2 | 0.090 |
Why?
|
| Cross-Cultural Comparison | 1 | 1990 | 15 | 0.090 |
Why?
|
| Child Behavior Disorders | 1 | 1990 | 18 | 0.090 |
Why?
|
| Risk Adjustment | 1 | 2010 | 34 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2009 | 6 | 0.090 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2009 | 2 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 6 | 0.090 |
Why?
|
| International Cooperation | 1 | 2009 | 17 | 0.090 |
Why?
|
| Risk | 3 | 2012 | 552 | 0.090 |
Why?
|
| Nausea | 1 | 2009 | 7 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 2009 | 7 | 0.090 |
Why?
|
| Vomiting | 1 | 2009 | 11 | 0.090 |
Why?
|
| Influenza A virus | 1 | 2009 | 14 | 0.090 |
Why?
|
| Health Care Rationing | 1 | 2009 | 14 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2009 | 25 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 86 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2009 | 17 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 249 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2009 | 3 | 0.090 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 32 | 0.080 |
Why?
|
| Thoracoscopy | 1 | 2008 | 3 | 0.080 |
Why?
|
| Waiting Lists | 2 | 2009 | 11 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 1 | 0.080 |
Why?
|
| Delphi Technique | 1 | 2008 | 31 | 0.080 |
Why?
|
| Forced Expiratory Volume | 1 | 2008 | 31 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 11 | 0.080 |
Why?
|
| Reference Standards | 2 | 2006 | 17 | 0.080 |
Why?
|
| Life Expectancy | 2 | 2017 | 33 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 2 | 0.080 |
Why?
|
| Omalizumab | 1 | 2007 | 4 | 0.080 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2007 | 2 | 0.080 |
Why?
|
| Inflammation | 1 | 2008 | 61 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 129 | 0.080 |
Why?
|
| Genetic Counseling | 2 | 1999 | 36 | 0.080 |
Why?
|
| Child | 4 | 2017 | 2519 | 0.070 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2017 | 2 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 1986 | 1 | 0.070 |
Why?
|
| Abdominal Neoplasms | 1 | 1986 | 2 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 44 | 0.070 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2006 | 16 | 0.070 |
Why?
|
| Calcaneus | 1 | 2006 | 5 | 0.070 |
Why?
|
| Physicians | 2 | 2016 | 143 | 0.070 |
Why?
|
| Social Support | 2 | 2019 | 211 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2005 | 20 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2015 | 961 | 0.070 |
Why?
|
| Self Report | 2 | 2019 | 252 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2006 | 87 | 0.070 |
Why?
|
| Polysaccharides | 2 | 2017 | 3 | 0.060 |
Why?
|
| Heart-Lung Transplantation | 1 | 2005 | 2 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2005 | 21 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 2 | 2020 | 79 | 0.060 |
Why?
|
| Airway Obstruction | 1 | 2004 | 1 | 0.060 |
Why?
|
| Exercise Tolerance | 1 | 2004 | 13 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1164 | 0.060 |
Why?
|
| Dyspnea | 1 | 2004 | 43 | 0.060 |
Why?
|
| Australia | 2 | 2014 | 20 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 30 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 127 | 0.060 |
Why?
|
| Occult Blood | 2 | 2021 | 159 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 2003 | 37 | 0.060 |
Why?
|
| Embolism, Air | 1 | 2003 | 1 | 0.060 |
Why?
|
| Oxygen | 1 | 2023 | 16 | 0.060 |
Why?
|
| Arteries | 1 | 2003 | 8 | 0.060 |
Why?
|
| Penicillanic Acid | 1 | 2003 | 1 | 0.060 |
Why?
|
| Piperacillin | 1 | 2003 | 1 | 0.060 |
Why?
|
| Linear Models | 3 | 2010 | 240 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2022 | 10 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 155 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2022 | 70 | 0.050 |
Why?
|
| Ontario | 1 | 2002 | 15 | 0.050 |
Why?
|
| Sexuality | 1 | 2002 | 11 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 62 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 49 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 56 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2002 | 82 | 0.050 |
Why?
|
| Inhalation Exposure | 1 | 2001 | 5 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 2001 | 37 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2001 | 20 | 0.050 |
Why?
|
| Occupational Exposure | 1 | 2001 | 56 | 0.050 |
Why?
|
| beta-Lactams | 1 | 2000 | 1 | 0.050 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2000 | 3 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2000 | 13 | 0.050 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2000 | 4 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2000 | 7 | 0.050 |
Why?
|
| Education | 1 | 2020 | 18 | 0.050 |
Why?
|
| Patient Participation | 1 | 2022 | 143 | 0.050 |
Why?
|
| Pedigree | 2 | 1999 | 55 | 0.050 |
Why?
|
| Resource Allocation | 1 | 2020 | 6 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2000 | 64 | 0.050 |
Why?
|
| Pregnancy | 3 | 2000 | 1484 | 0.050 |
Why?
|
| Health Policy | 2 | 2015 | 135 | 0.050 |
Why?
|
| Organizational Objectives | 1 | 2019 | 19 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 35 | 0.040 |
Why?
|
| Thoracotomy | 1 | 1999 | 1 | 0.040 |
Why?
|
| Fees and Charges | 1 | 1999 | 5 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 1999 | 160 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 1999 | 162 | 0.040 |
Why?
|
| Obstetrics | 1 | 1999 | 24 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 1999 | 73 | 0.040 |
Why?
|
| Family Practice | 1 | 1999 | 58 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 1998 | 6 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 1998 | 26 | 0.040 |
Why?
|
| Mortality | 2 | 2016 | 121 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1997 | 1 | 0.040 |
Why?
|
| Receptors, Angiotensin | 1 | 1997 | 4 | 0.040 |
Why?
|
| Psychometrics | 2 | 2005 | 120 | 0.040 |
Why?
|
| Albuminuria | 1 | 1997 | 39 | 0.040 |
Why?
|
| Enoxaparin | 1 | 2017 | 1 | 0.040 |
Why?
|
| Factor Xa Inhibitors | 1 | 2017 | 10 | 0.040 |
Why?
|
| South Carolina | 1 | 2017 | 16 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1997 | 3 | 0.040 |
Why?
|
| Smoking Prevention | 1 | 1997 | 57 | 0.040 |
Why?
|
| Health Promotion | 2 | 2016 | 295 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2012 | 1428 | 0.040 |
Why?
|
| Organizational Policy | 1 | 2016 | 18 | 0.040 |
Why?
|
| Warfarin | 1 | 2017 | 74 | 0.040 |
Why?
|
| Comprehension | 1 | 2016 | 21 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 32 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2017 | 235 | 0.040 |
Why?
|
| Patient Compliance | 1 | 1999 | 303 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2017 | 319 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 43 | 0.040 |
Why?
|
| Minority Groups | 2 | 2013 | 103 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 38 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1995 | 3 | 0.030 |
Why?
|
| Immunotherapy | 1 | 1995 | 7 | 0.030 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1995 | 18 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 13 | 0.030 |
Why?
|
| Spirometry | 1 | 2015 | 32 | 0.030 |
Why?
|
| Health Education | 1 | 2016 | 118 | 0.030 |
Why?
|
| Syndrome | 1 | 2015 | 31 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 29 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 75 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 46 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2014 | 1 | 0.030 |
Why?
|
| Brazil | 1 | 2014 | 5 | 0.030 |
Why?
|
| Models, Economic | 1 | 2014 | 21 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 29 | 0.030 |
Why?
|
| North America | 1 | 2014 | 42 | 0.030 |
Why?
|
| Cost Savings | 1 | 2014 | 25 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 15 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 43 | 0.030 |
Why?
|
| Motivation | 1 | 2015 | 133 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2016 | 280 | 0.030 |
Why?
|
| Health Services | 1 | 2014 | 111 | 0.030 |
Why?
|
| Grounded Theory | 1 | 2012 | 5 | 0.030 |
Why?
|
| Uncertainty | 1 | 2012 | 8 | 0.030 |
Why?
|
| Suicide | 1 | 1994 | 126 | 0.030 |
Why?
|
| Fear | 1 | 2012 | 13 | 0.030 |
Why?
|
| Dementia | 1 | 1994 | 103 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 9 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2012 | 22 | 0.030 |
Why?
|
| Vitamin K | 1 | 2012 | 15 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 22 | 0.030 |
Why?
|
| Orthopedic Procedures | 1 | 2012 | 6 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2012 | 81 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 16 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2012 | 53 | 0.030 |
Why?
|
| Markov Chains | 1 | 2011 | 26 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 114 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 35 | 0.020 |
Why?
|
| African Americans | 1 | 1994 | 485 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 205 | 0.020 |
Why?
|
| African Continental Ancestry Group | 1 | 2012 | 165 | 0.020 |
Why?
|
| Personality Disorders | 1 | 1990 | 2 | 0.020 |
Why?
|
| Multi-Institutional Systems | 1 | 2010 | 2 | 0.020 |
Why?
|
| Puerto Rico | 1 | 1990 | 5 | 0.020 |
Why?
|
| Alcoholism | 1 | 1994 | 346 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2010 | 60 | 0.020 |
Why?
|
| Poverty | 1 | 2012 | 177 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1990 | 127 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1997 | 742 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2010 | 97 | 0.020 |
Why?
|
| Tuberculin Test | 1 | 2009 | 1 | 0.020 |
Why?
|
| Isoniazid | 1 | 2009 | 3 | 0.020 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2009 | 3 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 2009 | 6 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 4 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 248 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2009 | 8 | 0.020 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2009 | 5 | 0.020 |
Why?
|
| Medicaid | 1 | 2010 | 206 | 0.020 |
Why?
|
| HIV Infections | 1 | 1995 | 682 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2008 | 4 | 0.020 |
Why?
|
| Diagnostic Techniques, Respiratory System | 1 | 2007 | 4 | 0.020 |
Why?
|
| Sweden | 1 | 2007 | 18 | 0.020 |
Why?
|
| Anal Canal | 1 | 2006 | 7 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2006 | 47 | 0.020 |
Why?
|
| Age of Onset | 1 | 2006 | 82 | 0.020 |
Why?
|
| Hip | 1 | 2006 | 9 | 0.020 |
Why?
|
| Spine | 1 | 2006 | 7 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2006 | 36 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2006 | 59 | 0.020 |
Why?
|
| Bias | 1 | 2006 | 109 | 0.020 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2005 | 1 | 0.020 |
Why?
|
| Kidney | 1 | 2005 | 53 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2004 | 67 | 0.010 |
Why?
|
| Direct Service Costs | 1 | 2003 | 10 | 0.010 |
Why?
|
| Drug Compounding | 1 | 2003 | 3 | 0.010 |
Why?
|
| Forecasting | 1 | 2004 | 77 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2003 | 89 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2004 | 265 | 0.010 |
Why?
|
| London | 1 | 1999 | 7 | 0.010 |
Why?
|
| Pregnancy, High-Risk | 1 | 1999 | 4 | 0.010 |
Why?
|
| Maternal Age | 1 | 1999 | 79 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1997 | 78 | 0.010 |
Why?
|
| Genotype | 1 | 1997 | 251 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1995 | 4 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1995 | 3 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 14 | 0.010 |
Why?
|
| Eosinophils | 1 | 1995 | 9 | 0.010 |
Why?
|
| Prenatal Care | 1 | 1996 | 136 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 33 | 0.010 |
Why?
|
| Demography | 1 | 1994 | 106 | 0.010 |
Why?
|
| Adolescent Behavior | 1 | 1994 | 130 | 0.010 |
Why?
|
| European Continental Ancestry Group | 1 | 1994 | 559 | 0.010 |
Why?
|